Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) criteria, active suicidal ideation with intent, and need for psychiatric hospitalization. Patients were randomized 1:1 to esketamine 84 mg or placebo nasal spray twice-weekly for 4 weeks, each with comprehensive standard-of-care treatment (initial psychiatric hospitalization and newly initiated or optimized oral antidepressant[s] therapy). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale (MADRS) total score (primary endpoint) was analyzed using analysis of covariance (ANCOVA), and change in Clinical Global Impression of Severity of Suicidality Revised version (CGI-SS-r; key secondary endpoint) score was analyzed using ANCOVA on ranks with treatment difference estimated using the Hodges-Lehmann estimate. RESULTS: Greater improvement in MADRS total score was observed with esketamine + standard-of-care versus placebo + standard-of-care at 24 hours (least-squares mean difference [SE]: -3.8 [1.39]; 95% CI, -6.56 to -1.09; 2-sided P = .006), as well as at earlier (4 hours) and later time points during 4-week double-blind treatment. The difference between groups in the severity of suicidality was not statistically significant (median of treatment difference [95% CI]: 0.0 [-1.00 to 0.00]; 2-sided P = .107). The most common adverse events among esketamine-treated patients were dizziness, dissociation, headache, nausea, and somnolence. CONCLUSIONS: These findings demonstrate rapid and robust efficacy of esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who have active suicidal ideation with intent. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03039192.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“Most recently, Fu and colleagues demonstrated moderately significant AD effects with adjunct intranasal (IN) esketamine but failed to demonstrate an effect for suicidality, the trial’s other primary outcome.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
In the citing paper
“In 2019, esketamine nasal spray (marketed as Spravato) was approved as an adjunctive AD treatment for TRD in the United States and the European Union, becoming the first novel-acting antidepressant approved in decades [104,105].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Kessler, R. C. (2005) · JAMA · doi:10.1001/jama.293.20.2487 · Cited by 1,073
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citationThe European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390
Deisenhammer, E. A., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03904 · Cited by 315
Holma, K. M., Melartin, T. K., Haukka, J., Holma, I. A. K., Sokero, T. P., & Isometsä, E. T. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09050627 · Cited by 248
Deisenhammer, E., Ing, C.-M., Strauss, R., Kemmler, G., Hinterhuber, H., & Weiss, E. M. (2009) · PubMed · Cited by 237
Lifetime suicide risk in major depression: sex and age determinants
Blair-West, G. W., Cantor, C. H., Mellsop, G. W., & Eyeson-Annan, M. L. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00004-x · Cited by 233
Suicide Attempts Among Patients Starting Depression Treatment With Medications or Psychotherapy
Simon, G. E., & Savarino, J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1029 · Cited by 168
Cited by
Items 201–300 of 375
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.082
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.074
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.093
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.028
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.026
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.029
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.035
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.015
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.044
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.001
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.034
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.089
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.016
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.049
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.061
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.048
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.019
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.066
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.052
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.031
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.014
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.075
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.043
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.077
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.063
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.064
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.081
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.078
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.054
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.037
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.021
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.090
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.062
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.020
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.088
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.070
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.011
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.080
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.095
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.094
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.073
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.098
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.012
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.027
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.036
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.085
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.087
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.040
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.076
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.010
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.069
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.060
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.072
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.050
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.053
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.033
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.059
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.056
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.096
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.099
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.025
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.022
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.030
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.023
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.068
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.041
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.092
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.004
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.067
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.039
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.047
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.065
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.084
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.002
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.057
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.013
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.003
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.079
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.091
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.042
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.006
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.038
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.005
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.100
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.110
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0152
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0145
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0128
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.119
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0106
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0144
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0143
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.146
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0132
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0147
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.113
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0130
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.101
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.115
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.0156
Metadata
- Authors
- Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M.
- Affiliations
- Janssen Research & Development (United States) (US)
- Yale University (US)
- Corresponding author
- Fu, Dong-Jing
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-05-12
- Volume
- 81
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3025905746
- Cited by
- 376
- References
- 13
- Citations by year
- 2026: 30 · 2025: 34 · 2024: 32 · 2023: 50 · 2022: 34 · 2021: 30 · 2020: 166
- FWCI
- 41.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, nasal spray, major depressive disorder, suicidal ideation, rapid-acting antidepressants, psychiatric hospitalization, antidepressant-resistant depression, depressive symptom reduction, adverse events
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Young Adult, Suicidal Ideation, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.